Legal & General Group Plc Lowers Holdings in Pfizer Inc. $PFE

Legal & General Group Plc reduced its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,233,122 shares of the biopharmaceutical company's stock after selling 272,441 shares during the period. Legal & General Group Plc owned 0.76% of Pfizer worth $1,041,054,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank increased its position in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. raised its holdings in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock valued at $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC raised its holdings in Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,480,000 after buying an additional 31,896 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 2.0%

NYSE PFE opened at $28.53 on Wednesday. The stock has a market cap of $162.60 billion, a PE ratio of 37.54 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The business has a 50 day moving average price of $25.39 and a two-hundred day moving average price of $26.27. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.0%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PFE shares. Wolfe Research reiterated an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Weiss Ratings downgraded shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer has an average rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source